Trial Profile
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms QUARTZ II-III
- Sponsors AbbVie
- 18 Jul 2017 Status changed from active, no longer recruiting to completed.
- 20 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 20 May 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.